Iovance beruft Noah Berkowitz zum Chief Medical Officer (CMO)

• Noah Berkowitz zum Chief Medical Officer ernannt, wirksam per 30. September 2026.
• Zuvor Chief Medical Officer bei Arvinas; verantwortete die klinische Strategie bis zur ersten FDA-Zulassung einer Proteinabbau-Therapie.
• Davor Senior Vice President, Therapeutic Area Head Hämatologie bei Bristol Myers Squibb; mitverantwortlich für Zulassungen der CAR-T-Therapien Abecma, Breyanzi.
• Frühere Stationen in der klinischen Entwicklung bei Novartis; Onkologie-Fellowship am National Cancer Institute.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837591) on October 01, 2026, and is solely responsible for the information contained therein.